OTC Markets OTCQB - Delayed Quote USD

Satellos Bioscience Inc. (MSCLF)

0.4820

0.0000

(0.00%)

At close: May 9 at 4:00:00 PM EDT

Satellos to Present at the CureDuchenne FUTURES National Conference

TORONTO, May 07, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the CureDuchenne FUTURES National Conference, taking place in San Antonio, TX, from May 22 to 25.

Business Wire 4 days ago

MSCLF
0.00%
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 29, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6.

Business Wire 12 days ago

MSCLF
0.00%
Satellos to Participate in Two April Investor Conferences

TORONTO, April 02, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present and participate at the following investor conferences in April:

Business Wire last month

MSCLF
0.00%
Satellos Bioscience (TSE:MSCL) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. last month

MSCLF
0.00%
Satellos Bioscience: Q4 Earnings Snapshot

TORONTO (AP) — Satellos Bioscience Inc. MSCLF) on Wednesday reported a loss of $849,000 in its fourth quarter. On a per-share basis, the Toronto-based company said it had a loss of 1 cent.

Associated Press Finance last month

MSCLF
0.00%
Satellos Reports 2024 Financial Results and Highlights Company Progress

TORONTO, March 26, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today its financial results and corporate highlights for the fourth quarter ended December 31, 2024. All references to currency in this press release are in Canadian dollars unless otherwise noted.

Business Wire last month

MSCLF
0.00%
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

TORONTO, March 19, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced initial Phase 1 data in an oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas.

Business Wire last month

MSCLF
0.00%
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

TORONTO, February 18, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced an oral presentation at the upcoming 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 16-19 in Dallas.

Business Wire 2 months ago

MSCLF
0.00%
Satellos concludes MAD cohort enrolment for Phase I trial of SAT-3247

Satellos is on track to submit a Phase II investigational new drug filing by the end of the first quarter.

Clinical Trials Arena 2 months ago

MSCLF
0.00%
Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial

Satellos Bioscience (MSCL.TO) on Monday said it has completed enrollment of all four multiple-ascend

PREMIUM
MT Newswires 2 months ago

MSCLF
0.00%
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

TORONTO, February 10, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced it has completed enrollment of all four multiple-ascending dose (MAD) cohorts for the Phase 1 clinical trial of SAT-3247 in healthy volunteers.

Business Wire 2 months ago

MSCLF
0.00%
Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

TORONTO, February 04, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually February 11-12, 2025.

Business Wire 3 months ago

MSCLF
0.00%
Satellos Bioscience And 2 Other TSX Penny Stocks To Watch

As 2025 begins, the Canadian market reflects on a stellar year with the TSX gaining 18%, driven by strong economic growth and rising corporate profits. In this climate, investors are increasingly considering diverse opportunities, including penny stocks—an often overlooked yet intriguing segment of the market. While traditionally associated with high risk, these smaller or newer companies can offer unique growth potential when backed by robust financials and solid fundamentals.

Simply Wall St. 4 months ago

MSCLF
0.00%

AZMTF

ORRCF
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Bloom Burton & Co. Inc. (Bloom Burton) announces that, today, it acquired 1,692,250 common shares (Shares) of Satellos Bioscience Inc. (Corporation) in connection with a public offering of the Corporation by way of a prospectus supplement dated December 17, 2024 to the short form prospectus dated April 7, 2024. Bloom Burton purchased the Shares at a price of $0.90 per Share for total consideration of ...

Newsfile 4 months ago

MSCLF
0.00%
Satellos Announces Closing of US$40M Public Offering

TORONTO, December 20, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced that it has closed an equity offering, issuing a total of 63,285,000 equity securities for gross proceeds of approximately $57 million (USD$40 million) (the "Offering").

Business Wire 4 months ago

MSCLF
0.00%
Satellos Priced US$40 Million Overnight Marketed Public Offering

Satellos Bioscience Inc. (MSCL.TO), a public biotech company, that saw its shares rise 2% yesterday,

PREMIUM
MT Newswires 4 months ago

MSCLF
0.00%
Satellos Announces Pricing of US$40M Overnight Marketed Public Offering

TORONTO, December 17, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce the pricing and terms of its previously announced overnight marketed public offering of common shares of the Company ("Common Shares") or pre-funded common share purchase warrants ("Pre-Funded Warrants" and, together with the Comm

Business Wire 4 months ago

MSCLF
0.00%
Satellos Announces Overnight Marketed Public Offering of Common Shares

TORONTO, December 16, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has filed a preliminary prospectus supplement (the "Preliminary Prospectus Supplement") and intends to file a subsequent prospectus supplement (the "Prospectus Supplement") to its short form base shelf prospectus dated April 7, 2

Business Wire 4 months ago

MSCLF
0.00%
Satellos doses first DMD subject in Phase Ib trial

The Phase I clinical trial of SAT-3247 is structured in two components.

Clinical Trials Arena 4 months ago

MSCLF
0.00%
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

TORONTO, December 11, 2024--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that the first participant with Duchenne muscular dystrophy ("DMD") has been dosed in the Phase 1b safety and pharmacokinetics ("PK") trial in DMD patients.

Business Wire 4 months ago

MSCLF
0.00%

Performance Overview

Return	MSCLF	S&P/TSX Composite index (^GSPTSE)
YTD	-18.03%	+2.99%
1-Year	+50.16%	+13.33%
3-Year	-46.44%	+26.79%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Satellos Bioscience Inc. (MSCLF)

Satellos to Present at the CureDuchenne FUTURES National Conference

Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference

Satellos to Participate in Two April Investor Conferences

Satellos Bioscience (TSE:MSCL) Is In A Good Position To Deliver On Growth Plans

Satellos Bioscience: Q4 Earnings Snapshot

Satellos Reports 2024 Financial Results and Highlights Company Progress

Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos concludes MAD cohort enrolment for Phase I trial of SAT-3247

Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial

Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers

Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Satellos Bioscience And 2 Other TSX Penny Stocks To Watch

Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

Satellos Announces Closing of US$40M Public Offering

Satellos Priced US$40 Million Overnight Marketed Public Offering

Satellos Announces Pricing of US$40M Overnight Marketed Public Offering

Satellos Announces Overnight Marketed Public Offering of Common Shares

Satellos doses first DMD subject in Phase Ib trial

Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247

Performance Overview